Benign pancreatic hyperenzymemia-Gullo's syndrome: focus on this clinical challenge. A monocentric retrospective study.


Journal

Minerva medica
ISSN: 1827-1669
Titre abrégé: Minerva Med
Pays: Italy
ID NLM: 0400732

Informations de publication

Date de publication:
Dec 2019
Historique:
pubmed: 23 10 2019
medline: 11 2 2020
entrez: 23 10 2019
Statut: ppublish

Résumé

An abnormal and chronic rise of pancreatic enzymes in the blood is most often due to pancreatic diseases, primarily inflammatory or neoplastic, or to numerous extra-pancreatic pathologies. Benign chronic pancreatic hyperenzymemia was described for the first time - as a separate nosological entity - in 1996 by Lucio Gullo et al. They demonstrated the existence of a benign chronic pancreatic hyperenzymemia in asymptomatic subjects and without clinical implications; however, a follow-up of at least 1-2 years is necessary during which no specific symptomatology or morpho-functional impairment of the pancreas should occur, also evaluated through the aid of instrumental diagnostic investigations such as ultrasonography (US), computed tomography (CT) or magnetic resonance cholangio pancreatography (MRCP). This study was performed with the analysis of a group of 43 subjects arrived at the observation of the Gastroenterology Team of Policlinico Hospital G. Rodolico in Catania-Italy which presented a chronic pancreatic hyperenzymemia, in order to establish the actual benignity of this condition over time. During the follow-up, pancreatic alterations and hyperenzymemia were found in 10 patients, while hyperenzymemia was not associated with pancreatic modification in 33 patients. Because of this enzymatic elevation - often conspicuous and lasting - the patient is often particularly anxious. For the same reason, the patient frequently undergoes very expensive laboratory and instrumental diagnostic methods. Good knowledge of the syndrome makes it possible to manage the event more rationally, also to reduce management costs to a minimum.

Sections du résumé

BACKGROUND BACKGROUND
An abnormal and chronic rise of pancreatic enzymes in the blood is most often due to pancreatic diseases, primarily inflammatory or neoplastic, or to numerous extra-pancreatic pathologies. Benign chronic pancreatic hyperenzymemia was described for the first time - as a separate nosological entity - in 1996 by Lucio Gullo et al. They demonstrated the existence of a benign chronic pancreatic hyperenzymemia in asymptomatic subjects and without clinical implications; however, a follow-up of at least 1-2 years is necessary during which no specific symptomatology or morpho-functional impairment of the pancreas should occur, also evaluated through the aid of instrumental diagnostic investigations such as ultrasonography (US), computed tomography (CT) or magnetic resonance cholangio pancreatography (MRCP).
METHODS METHODS
This study was performed with the analysis of a group of 43 subjects arrived at the observation of the Gastroenterology Team of Policlinico Hospital G. Rodolico in Catania-Italy which presented a chronic pancreatic hyperenzymemia, in order to establish the actual benignity of this condition over time.
RESULTS RESULTS
During the follow-up, pancreatic alterations and hyperenzymemia were found in 10 patients, while hyperenzymemia was not associated with pancreatic modification in 33 patients.
CONCLUSIONS CONCLUSIONS
Because of this enzymatic elevation - often conspicuous and lasting - the patient is often particularly anxious. For the same reason, the patient frequently undergoes very expensive laboratory and instrumental diagnostic methods. Good knowledge of the syndrome makes it possible to manage the event more rationally, also to reduce management costs to a minimum.

Identifiants

pubmed: 31638356
pii: S0026-4806.19.06046-4
doi: 10.23736/S0026-4806.19.06046-4
doi:

Substances chimiques

Enzymes 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

490-498

Auteurs

Roberto Catanzaro (R)

Section of Gastroenterology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy - rcatanza@unict.it.
Vittorio Emanuele Policlinic Hospital, Gaspare Rodolico University Hospital, Catania, Italy - rcatanza@unict.it.

Morena Sciuto (M)

Section of Gastroenterology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Vittorio Emanuele Policlinic Hospital, Gaspare Rodolico University Hospital, Catania, Italy.

Giuseppe Adamo (G)

Section of Gastroenterology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Vittorio Emanuele Policlinic Hospital, Gaspare Rodolico University Hospital, Catania, Italy.

Martina Guarrera (M)

Paolo Giaccone University Hospital, Palermo, Italy.

Francesco Marotta (F)

ReGenera R&D International for Aging Intervention & San Babila Clinic, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH